Immunoconjugates: Lessons from animal models

S. Canevari, M. Colombatti, M. I. Colnaghi

Research output: Contribution to journalArticlepeer-review

Abstract

Monoclonal antibody-mediated cancer therapy has evolved through a challenging chain of problems and solutions. The very limited therapeutic success obtained with unarmed monoclonal antibodies has increased the interest in different antibody-based targeting strategies, and numerous preclinical and even clinical studies with immunoconjugates have now been conducted. We comment here on the messages implicit in a recent report on a doxorubicin-anti-carcinoma antibody conjugate and from several other studies.

Original languageEnglish
Pages (from-to)698-701
Number of pages4
JournalAnnals of Oncology
Volume5
Issue number8
Publication statusPublished - 1994

Keywords

  • Immunoconjugates
  • Monoclonal antibodies
  • Preclinical models

ASJC Scopus subject areas

  • Cancer Research
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Hematology
  • Oncology
  • Public Health, Environmental and Occupational Health
  • Neuropsychology and Physiological Psychology

Fingerprint Dive into the research topics of 'Immunoconjugates: Lessons from animal models'. Together they form a unique fingerprint.

Cite this